Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer

Overview

Journal Cancer Res Treat

Specialty Oncology

Date 2015 Feb 27

PMID 25715768

Citations 14

Authors

Seong-Hoon Yoon

Yoo-Duk Choi

In-Jae Oh

Kyu-Sik Kim

Hayoung Choi

Jinsun Chang

Hong-Joon Shin

Cheol-Kyu Park

Young-Chul Kim

Affiliations

Soon will be listed here.

Abstract

Purpose: Direct sequencing (DS) is the standard method for detection of epidermal growth factor receptor (EGFR) gene mutation in non-small cell lung cancer (NSCLC); however, low detection sensitivity is a problem. The aim of this study is to demonstrate higher detection rate of EGFR gene mutation with peptide nucleic acid (PNA) clamping compared with DS.

Materials And Methods: This is a single arm, prospective study for patients with stage IIIB/IV or relapsed NSCLC. Using tumor DNA from 138 patients, both DS and PNA clamping for EGFR gene in exon 18, 19, 20, and 21 were performed. Discrepant results between the two methods were verified using Cobas and a mutant enrichment based next generation sequencing (NGS). Patients with activating mutations were treated with EGFR tyrosine kinase inhibitor (EGFR-TKI, gefitinib, or erlotinib) as first line treatment.

Results: Of 138 paired test sets, 24 (17.4%) and 45 (32.6%) cases with activating mutations were detected by DS and PNA clamping, respectively. The difference of detection rate between the two methods was 15.2% (95% confidence interval, 8.7% to 17.8%; p < 0.001). Between the two methods, 25 cases showed discrepant results (n=23, PNA+/DS-; n=2, PNA-/DS+). Mutations were confirmed by Cobas or NGS in 22 of 23 PNA+/DS- cases. The response rates to EGFR-TKI were 72.2% in the PNA+/DS+ group and 85.0% in the PNA+/DS- group.

Conclusion: PNA clamping showed a significantly higher detection rate of EGFR gene mutation compared with DS. Higher sensitivity of PNA clamping was not compromised by the loss of predictive power of response to EGFR-TKI.

Citing Articles

Genetic Alterations and Risk Factors for Recurrence in Patients with Non-Small Cell Lung Cancer Who Underwent Complete Surgical Resection.

Park H, Choi Y, Yun J, Song S, Na K, Yoon J Cancers (Basel). 2023; 15(23).

PMID: 38067382 PMC: 10705717. DOI: 10.3390/cancers15235679.

Efficacy and dose of afatinib in patients with non-small cell lung cancer after failure of prior gefitinib or erlotinib treatment.

Choi H, Lee J, Oh H, Kim M, Kho B, Park C Thorac Cancer. 2021; 12(10):1598-1604.

PMID: 33811467 PMC: 8107028. DOI: 10.1111/1759-7714.13957.

Bronchial brushing cytology is comparable to bronchial biopsy for epidermal growth factor receptor mutation test in non-small cell lung cancer.

Koo J, Kim N, Lee T, Choi Y Cytojournal. 2020; 17:16.

PMID: 33093852 PMC: 7568225. DOI: 10.25259/Cytojournal_73_2019.

Sensitive detection of low-abundance in-frame deletions in EGFR exon 19 using novel wild-type blockers in real-time PCR.

Ren X, Liu D, Guo H, Wang L, Zhao N, Su N Sci Rep. 2019; 9(1):8276.

PMID: 31164704 PMC: 6547704. DOI: 10.1038/s41598-019-44792-1.

Prognostic value of quantitative measurement of EGFR mutation using peptide nucleic acid clamping in advanced EGFR mutant non-small cell lung cancer patients.

Kim I, Eom J, Jo E, Mok Ki Uk J, Lee K, Kim K Thorac Cancer. 2019; 10(7):1561-1566.

PMID: 31148357 PMC: 6610248. DOI: 10.1111/1759-7714.13101.

References

Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R . Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011; 6(4):707-15. DOI: 10.1097/JTO.0b013e31820a3a6b. View

Han H, Lim S, An J, Lee K, Choe K, Lee K . Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity. J Thorac Oncol. 2011; 7(2):355-64. DOI: 10.1097/JTO.0b013e31823c4c1b. View

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H . Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362(25):2380-8. DOI: 10.1056/NEJMoa0909530. View

Fukuoka M, Wu Y, Thongprasert S, Sunpaweravong P, Leong S, Sriuranpong V . Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011; 29(21):2866-74. DOI: 10.1200/JCO.2010.33.4235. View

Lee J, Jang S, Lee K, Kim Y . Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. Cancer Res Treat. 2013; 45(2):79-85. PMC: 3710966. DOI: 10.4143/crt.2013.45.2.79. View

Pao W, Ladanyi M . Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res. 2007; 13(17):4954-5. DOI: 10.1158/1078-0432.CCR-07-1387. View

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E . Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3):239-46. DOI: 10.1016/S1470-2045(11)70393-X. View

Tsao M, Sakurada A, Cutz J, Zhu C, Kamel-Reid S, Squire J . Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med. 2005; 353(2):133-44. DOI: 10.1056/NEJMoa050736. View

Yu H, Arcila M, Rekhtman N, Sima C, Zakowski M, Pao W . Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013; 19(8):2240-7. PMC: 3630270. DOI: 10.1158/1078-0432.CCR-12-2246. View

10.

Lee H, Xu X, Kim H, Jin Y, Sun P, Kim J . Comparison of Direct Sequencing, PNA Clamping-Real Time Polymerase Chain Reaction, and Pyrosequencing Methods for the Detection of EGFR Mutations in Non-small Cell Lung Carcinoma and the Correlation with Clinical Responses to EGFR Tyrosine Kinase.... Korean J Pathol. 2013; 47(1):52-60. PMC: 3589609. DOI: 10.4132/KoreanJPathol.2013.47.1.52. View

11.

Takezawa K, Pirazzoli V, Arcila M, Nebhan C, Song X, de Stanchina E . HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov. 2012; 2(10):922-33. PMC: 3473100. DOI: 10.1158/2159-8290.CD-12-0108. View

12.

ODonnell P, Ferguson J, Shyu J, Current R, Rehage T, Tsai J . Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. BMC Cancer. 2013; 13:210. PMC: 3660201. DOI: 10.1186/1471-2407-13-210. View

13.

Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21):2129-39. DOI: 10.1056/NEJMoa040938. View

14.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

15.

Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J . Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2009; 11(2):121-8. DOI: 10.1016/S1470-2045(09)70364-X. View

16.

Zhou C, Wu Y, Chen G, Feng J, Liu X, Wang C . Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12(8):735-42. DOI: 10.1016/S1470-2045(11)70184-X. View

17.

Dacic S . EGFR assays in lung cancer. Adv Anat Pathol. 2008; 15(4):241-7. DOI: 10.1097/PAP.0b013e31817bf5a9. View

18.

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

19.

Kim H, Lee K, Kim Y, Kim K, Yong Lee S, Jang T . Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Lung Cancer. 2011; 75(3):321-5. DOI: 10.1016/j.lungcan.2011.08.005. View